GSK wins FDA approval for OTC Flonase; KKR, Blackstone, TPG eye Sanofi's older meds;

@FiercePharma: Top-read on FierceVaccines Thursday: $GSK submits world's first malaria vaccine for EMA approval. Story | Follow @FiercePharma

@TracyStaton: CVS Caremark lays out case for new specialty-drug pricing approach in JAMA editorial. Abstract via JAMA | Follow @TracyStaton

@EricPFierce: Merck KGaA's second largest manufacturing plant is going up in China to make diabetes drugs. Article | Follow @EricPFierce

@CarlyHFierce: Love this headline via @BloombergNews: "Wall Street Junk Euphoria Backs Ackman's Allergan Dreams." Story via Bloomberg. | Follow @CarlyHFierce

> An $8.5 billion portfolio of Sanofi's ($SNY) off-patent drugs has drawn interest from private equity firms like KKR, Blackstone Group and TPG Capital, Bloomberg's sources say. Report

> The FDA has given GlaxoSmithKline ($GSK) approval to sell its Flonase allergy med over the counter. Report

> European regulators have recommended approval of Novo Nordisk's ($NVO) Xultophy, a combo pill of its Tresiba and Victoza. Release

> Some analysts are questioning whether GlaxoSmithKline's ($GSK) revamped sales model is responsible for slower-than-expected launches of new respiratory meds Breo and Anoro. Story

Medical Device News

@FierceMedDev: 3-D printing grows to scale within industry. Report | Follow @FierceMedDev

@StacyALawrence: Intuitive's surgical robot hit with another unfavorable study result. More | Follow @StacyALawrence

@VarunSaxena2: Boston Scientific hopes to capitalize on competitors' weaknesses. Story | Follow @VarunSaxena2

@MichaelGFierce: Most absorbent material on Earth gives poorly soluble drugs a boost. Article from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Fewer than half of American children are vaccinated against HPV, according to new estimates from the CDC. Story via The Atlantic | Follow @EmilyWFierce

> Covidien is popping the bubbly for positive Q3 numbers. More

> Varian, AngioDynamics fall on earnings disappointments. Story

> St. Jude laying off up to 270 workers in California. News

Biotech News

@FierceBiotech: We're looking for 2014's Fiercest women in biotech. More | Follow @FierceBiotech

@JohnCFierce: Good story. RT @JeanneWhalen: GSK is close to launching world's first malaria vaccine, but a rival is close behind. Story | Follow @JohnCFierce

@DamianFierce: EU's CHMP recommends Novo's fixed dose combo of a GLP-1 and Victoza, to be marketed as Xultophy. More | Follow @DamianFierce

@EmilyMFierce: GlaxoSmithKline steps closer to making world's first malaria vaccine. Article | Follow @EmilyMFierce

> Keryx touts its kidney drug with an FDA decision around the corner. More

> Two more biotechs limp onto Wall Street with discounted debuts. Story

> Novo's blockbuster diabetes combo nears EU approval. Article

And Finally... The prospect of chronic illness is more effective than the prospect of a shortened life in encouraging smokers to quit, a study found. Story (sub. req.)

Suggested Articles

It’s been a rocky road for BMS’ immuno-oncology duo in previously untreated lung cancer, but a new addition to the regimen might hold the ticket.

Novartis’ Zolgensma launch has been anything but boring: First a record price, then a data scandal and now a manufacturing-related delay in Europe.

As CEO Paul Hudson focuses Sanofi's R&D program on immuno-oncology and gene therapies, Sanofi is readying a vaccine plant to make viral vectors.